ACS1 antibody, FACL1 antibody, FACL2 antibody, LACS antibody, LACS1 antibody, LACS2 antibody, Acas antibody, Acas1 antibody, Acs antibody, FACS antibody, Facl2 antibody, ACS antibody, COAA antibody, zgc:110081 antibody, CER8 antibody, ECERIFERUM 8 antibody, LONG-CHAIN ACYL-COA SYNTHASE 1 antibody, T8I13.8 antibody, F13F21.14 antibody, F13F21_14 antibody, LATERAL ROOT DEVELOPMENT 2 antibody, LRD2 antibody, long-chain acyl-CoA synthetase 2 antibody, acyl-CoA synthetase long chain family member 1 antibody, acyl-CoA synthetase long-chain family member 1 antibody, acyl-CoA synthetase long chain family member 1a antibody, AMP-dependent synthetase and ligase family protein antibody, long-chain acyl-CoA synthetase 2 antibody, ACSL1 antibody, Acsl1 antibody, acsl1a antibody, LACS1 antibody, LACS2 antibody
Background
Long-chain acyl coenzyme A synthetase 1 (ACSL1) catalyzes the synthesis of acyl-CoA from long-chain fatty acids in an ATP-dependent manner. ACSL1 is a member of a family of long-chain acyl-CoA synthetases which differ in substrate preference, tissue expression, and subcellular localization. In mouse, ASCL1 is the major acyl-CoA enzyme in the heart, providing 60-90 % of heart ATP. Loss of ASCL1 either globally or in heart ventricles resulted in impaired fatty acid oxidation, activation of the mammalian target of rapamycin (mTOR), and cardiac hypertrophy.Synonyms: Acyl-CoA synthetase 1, FACL1, FACL2, LACS, LACS1, LACS2, Long-chain acyl-CoA synthetase 1, Long-chain acyl-CoA synthetase 2, Long-chain fatty acid-CoA ligase 2, Long-chain-fatty-acid--CoA ligase 1, Palmitoyl-CoA ligase 1, Palmitoyl-CoA ligase 2